GARPEC

There is a lack of high quality, standardised data on AB use and AMR in neonates and children worldwide.
This limits ability to develop sustainable and widely applicable strategies for minimising selection of AMR, defining effective antibiotic treatment approaches and instituting infection control measures.

What is GARPEC?

Global Antimicrobial Resistance, Prescribing, and Efficacy Among Neonates and Children

The GARPEC project is a Penta-sponsored global surveillance network focused on collection of data on neonatal and paediatric antimicrobial prescribing and resistance. Its main functions are to collect and analyse data on antimicrobial prescriptions among neonates and children and on the organisms causing blood stream infections in these populations, including their antibiotic/antifungal resistance patterns.

Why is GARPEC needed?

The network addresses the current lack of quality, standardised data on antimicrobial use and resistance among neonatal and paediatric patients, data which are essential for characterising the problem of antimicrobial resistance worldwide and developing effective treatment and control strategies at the local level.

What is GARPEC’s goal?

GARPEC aims to characterise antimicrobial prescription rates among neonatal and paediatric patients using periodic point prevalence surveys and to assess bloodstream infection (BSI) burden and resistance patterns among neonatal and paediatric patients using routinely collected laboratory data.

This project is funded by Penta.